isotype igg2b (mpc-11) control antibodies  (Bio X Cell)

Journal: JACC: Basic to Translational Science

Article Title: Cardiopathogenic T Cells Govern Progression and Functional Remodeling in Inflammatory Cardiomyopathy and Chronic Myocarditis

doi: 10.1016/j.jacbts.2025.101458

Figure Lengend Snippet: The Role of CD4 + T Cells in Cardiac Functional Remodeling (A) Experimental design. (B and C) Flow cytometric analysis of CD4 + T cells in peripheral blood of TCRM mice treated with IgG2b isotype control or anti-CD4 antibody. (D) Representative H&E and PSR-stained heart sections. (E) Myocarditis score and (F) quantification of PSR-positive area, in 8-week-old TCRM mice subjected to the indicated treatment. (G to J) Echocardiographic assessment of left ventricular morphology and function in 8-week-old TCRM mice treated with isotype control or anti-CD4 antibody. (G) LVID systole, (H) LVEF, (I) GCS, (J) GLS. (C, E to J) Pooled data from 3 independent experiments, including n = 12 anti-CD4-treated TCRM mice and n = 13 isotype-treated TCRM mice of which n = 5 progressed to iCMP. Statistical analysis was performed using C, unpaired 2-tailed Student’s t -test or Mann-Whitney U test and (E to J) 1-way analysis of variance with Tukey’s post hoc test or Kruskal-Wallis test with Dunnett’s multiple comparisons test. Boxplots as in . ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001. Abbreviations as in and .

Article Snippet: Mice were treated with 500 μg of anti-CD4 antibody (clone: YTS191, ECACC, 87072282) or IgG2b isotype control antibody (clone: MPC-11, ECACC, ATCC CCL-167) by intraperitoneal injection twice a week as demonstrated in the respective experiments.

Techniques: Functional Assay, Control, Staining, MANN-WHITNEY

Journal: Nature Communications

Article Title: Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma

doi: 10.1038/s41467-024-49718-8

Figure Lengend Snippet: a Experimental scheme for the treatment of mice bearing epithelial, mixed, and mesenchymal cSCCs with 200 µg/dose of IgG isotype control, anti-PD-L1, anti-PD-1, anti-CTLA-4, and anti-TIGIT antibodies, and 300 µg/dose of anti-CD8 and anti-NK1.1 antibodies (i.p. three times/week). All treatments started when engrafted tumors reached a volume of 65 mm 3 . b Growth kinetics of IgG control, anti-PD-L1, anti-PD-1, anti-PD-L1 + anti-CD8, and anti-PD-L1 + anti-NK-treated epithelial cSCCs ( n = 10 per group). c – f Percentage of c CD8 + T cells, d NK cells, e GzmB + CD8 + T cells, and f GzmB + NK cells in the indicated epithelial cSCCs ( n = 10 per group). g Growth kinetics of IgG control and anti-CTLA-4-treated epithelial cSCCs ( n = 10 per group). h – k Percentage of h CD8 + T cells, i NK cells, j GzmB + CD8 + T cells, and k GzmB + NK cells in IgG control and anti-CTLA-4-treated epithelial cSCCs ( n = 10 per group). l Growth kinetics of IgG control and anti-TIGIT-treated epithelial cSCCs ( n = 10 per group). m – p Percentage of m CD8 + T cells ( n = 10 per group), n NK cells ( n = 10 per group), o GzmB + CD8 + T cells ( n = 7 per group), and p GzmB + NK cells ( n = 7 per group) in IgG control and anti-TIGIT-treated epithelial cSCCs. q – s Percentage of GFP + EpCAM + and GFP + EpCAM − cancer cells in the indicated epithelial cSCCs ( n = 10 per group). All data are represented as the mean ± SD, and n values indicate independent tumors. P values are determined by two-way ANOVA test ( b , g , l ), one-way ANOVA with Dunnett’s multiple comparison test ( c – f , q ), and unpaired two-sided Student’s t -test ( h – k , m – p , r , s ). ns > 0.05: not significant. See Supplementary Fig. for the gating strategy ( c – f, h – k, m – s ). Source data are provided as a Source Data file.

Article Snippet: When tumors generated reached a volume of 65 mm 3 (5 × 5 mm), mice were randomly assigned to a control or ICB treatment group and treated intraperitoneally three times per week with a 200 μg/dose of mouse IgG2b isotype control (clone MPC-11, BioXCell, BE0086), polyclonal rat IgG isotype control (BE0094), anti-PD-L1 (clone 10F.9G2, BioXCell, BE0101), anti-PD-1 (clone RMP1-14, BioXCell, BE0146), anti-CTLA-4 (clone UC10-4F10-11, BioXCell, BE0032), and anti-TIGIT (clone 1G9, BioXCell, BE0274) antibodies for 21–28 days.

Techniques: Control, Comparison

Journal: Nature Communications

Article Title: Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma

doi: 10.1038/s41467-024-49718-8

Figure Lengend Snippet: a Growth kinetics of IgG control, anti-PD-L1, and anti-PD-1-treated mesenchymal cSCCs ( n = 10 per group). b – e Percentage of b CD8 + T cells, c NK cells, d GzmB + CD8 + T cells, and e GzmB + NK cells in IgG control, anti-PD-L1, and anti-PD-1-treated mesenchymal cSCCs ( n = 10 per group). f , k Growth kinetics of IgG control, ( f ) anti-CTLA-4, anti-CTLA-4 + anti-CD8, and anti-CTLA-4 + anti-NK or ( k ) anti-TIGIT, anti-TIGIT + anti-CD8, and anti-TIGIT + anti-NK-treated mesenchymal cSCCs ( n = 10 per group). For better visualization, this experiment has been separated into two graphs in which the IgG control group is the same. g – j , l , m Percentage of g , l CD8 + T cells, h , m NK cells, i GzmB + CD8 + T cells, and j GzmB + NK cells in the indicated mesenchymal cSCCs ( n = 10 per group). n, o Percentage of GFP + EpCAM + and GFP + EpCAM − cancer cells in the indicated mesenchymal cSCCs ( n = 10 per group). All data are represented as the mean ± SD, and n values indicate independent tumors. P values are determined by two-way ANOVA test ( a , f , k ) and one-way ANOVA with Dunnett’s multiple comparison test ( b – e , g – j , l – o ). ns > 0.05: not significant. See Supplementary Fig. for the gating strategy ( b – e , g – j , l – o ). Source data are provided as a Source Data file.

Article Snippet: When tumors generated reached a volume of 65 mm 3 (5 × 5 mm), mice were randomly assigned to a control or ICB treatment group and treated intraperitoneally three times per week with a 200 μg/dose of mouse IgG2b isotype control (clone MPC-11, BioXCell, BE0086), polyclonal rat IgG isotype control (BE0094), anti-PD-L1 (clone 10F.9G2, BioXCell, BE0101), anti-PD-1 (clone RMP1-14, BioXCell, BE0146), anti-CTLA-4 (clone UC10-4F10-11, BioXCell, BE0032), and anti-TIGIT (clone 1G9, BioXCell, BE0274) antibodies for 21–28 days.

Techniques: Control, Comparison

Journal: Nature Communications

Article Title: Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma

doi: 10.1038/s41467-024-49718-8

Figure Lengend Snippet: a Growth kinetics of IgG control and anti-PD-L1-treated mixed cSCCs ( n = 8 per group). b – e Percentage of b CD8 + T cells ( n = 8), c NK cells ( n = 8), d GzmB + CD8 + T cells ( n = 6), and e GzmB + NK cells ( n = 6) in IgG control and anti-PD-L1-treated mixed cSCCs. f Growth kinetics of IgG control and anti-CTLA-4-treated mixed cSCCs ( n = 8 per group). g – j Percentage of g CD8 + T cells ( n = 8), h NK cells ( n = 8), i GzmB + CD8 + T cells ( n = 6), and j GzmB + NK cells ( n = 6) in IgG control and anti-CTLA-4-treated mixed cSCCs. k Growth kinetics of IgG control, anti-PD-L1, anti-TIGIT, and anti-PD-L1 + anti-TIGIT-treated mixed cSCCs ( n = 10 per group). l – o Percentage of l CD8 + T cells ( n = 10), m NK cells ( n = 10), n GzmB + CD8 + T cells ( n = 7), and o GzmB + NK cells ( n = 7) in the indicated mixed cSCCs. p – r Percentage of GFP + EpCAM + and GFP + EpCAM − cancer cells in the indicated mixed cSCCs (PD-L1 and CTLA-4 experiments: n = 8 per group; PD-L1/TIGIT experiment: n = 10 per group). All data are represented as the mean ± SD, and n values indicate independent tumors. P values are determined by two-way ANOVA test ( a , f , k ), unpaired two-sided Student’s t -test ( b – e , g – j , p , q ), and one-way ANOVA with Dunnett’s multiple comparison test ( l – o , r ). See Supplementary Fig. for the gating strategy ( b – e , g – j , l – r ). Source data are provided as a Source Data file.

Article Snippet: When tumors generated reached a volume of 65 mm 3 (5 × 5 mm), mice were randomly assigned to a control or ICB treatment group and treated intraperitoneally three times per week with a 200 μg/dose of mouse IgG2b isotype control (clone MPC-11, BioXCell, BE0086), polyclonal rat IgG isotype control (BE0094), anti-PD-L1 (clone 10F.9G2, BioXCell, BE0101), anti-PD-1 (clone RMP1-14, BioXCell, BE0146), anti-CTLA-4 (clone UC10-4F10-11, BioXCell, BE0032), and anti-TIGIT (clone 1G9, BioXCell, BE0274) antibodies for 21–28 days.

Techniques: Control, Comparison